Nokof375 mg

Nokof 375 mg is indicated for- Acute bronchitis, Chronic bronchitis, Bronchial asthma, Upper respiratory tract inflammation (pharyngitis, laryngitis), Cystic fibrosis Bronchiectasis, Pulmonary tuberculosis, Drainage in chronic sinusitis and pneumonia, Drainage in otitis media in children.

Cough expectorants & mucolytics

Nokof 375 mg reduces goblet cell hyperplasia and therefore plays a role in the management of disorders characterised by abnormal mucous. Nokof 375 mg loosens thick sputum effectively by reducing its viscosity and thereby helps to expectorate that mucus more easily from the respiratory tract. The mucolytic action happens in several mechanisms. It breaks the disulphide bonds, which cross-link certain glycoprotein molecules in the mucus, the mucus produced under the influence of Nokof 375 mg has high sialomucin and low fucomucin content. This combined effect ultimately reduces the viscosity of the sputum and increases its volume.

Adult: Initially, 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.Child: 2-5 year: 62.5-125 mg 4 times daily; 6-12 year 250 mg tid.Should be taken with food.

Adult: Initially, 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.Child: 2-5 year: 62.5-125 mg 4 times daily; 6-12 year 250 mg tid.Should be taken with food.

Neither hazardous nor therapeutically useful interactions have been reported.

Contraindicated in active peptic ulceration and in patients with hypersensitivity to the drug.

Gastrointestinal discomfort, nausea, diarrhoea, gastrointestinal bleeding, palpitation, dizziness, headache, heartburn and skin rash may occur.

There is no information on the use of Nokof 375 mg during lactation. While there are no reports of teratogenic effects, the manufacturers do not recommend the use of Nokof 375 mg in the first trimester.

No specific precaution is recommended but Nokof 375 mg should be used with caution in patients with a recent history of peptic ulcer and recurrent gastrointestinal bleeding.

Symptoms: GI disturbance. Management: May perform gastric lavage, followed by observation.

Store in a cool and dry place protected from light.

Cough expectorants & mucolytics

Nokof 375 mg reduces goblet cell hyperplasia and therefore plays a role in the management of disorders characterised by abnormal mucous. Nokof 375 mg loosens thick sputum effectively by reducing its viscosity and thereby helps to expectorate that mucus more easily from the respiratory tract. The mucolytic action happens in several mechanisms. It breaks the disulphide bonds, which cross-link certain glycoprotein molecules in the mucus, the mucus produced under the influence of Nokof 375 mg has high sialomucin and low fucomucin content. This combined effect ultimately reduces the viscosity of the sputum and increases its volume.

There is no information on the use of Nokof 375 mg during lactation. While there are no reports of teratogenic effects, the manufacturers do not recommend the use of Nokof 375 mg in the first trimester.